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Abstract
This study investigated potential correlation between the inflammatory marker, Calprotectin, and a S.O.S 
questionnaire from forty-nine Autistic children. Symptom and behavioral questionnaires were completed 
contemporaneously with stool sample collection.
Mixed Model data analysis showed strong correlation between some questionnaire parameters and 
Calprotectin. ‘Need for a fixed routine’ was highly significantly correlated with Calprotectin (𝑝<0.00009) with 
Multivariate Coefficient of 3.227, whilst paradoxically ‘constipation’ indicated significant change (𝑝<0.02) with 
negative Multivariate Coefficient (-1.584). The negative ‘constipation’ appears to associate with the positive ‘need 
for a fixed routine’ indicating possibility of reciprocal, independent prediction of gastrointestinal inflammation.
Results suggest that ‘need for a fixed routine’ and ‘constipation’ be included in a screening questionnaire as 
independent predictors of bowel dysfunction in these children.
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Introduction
Autistic Spectrum Disorder (ASD) is a Pervasive Developmental Disorder (PDD) with 
abnormal or impaired development in reciprocal social interaction, abnormal or impaired social 
communication and social imagination [1-3].
There has been a considerable increase in the awareness of autism since first described by Dr 
Leo Kanner in 1943 [1,4,5]. However, treatment procedures that focus on the overall wellbeing 
of subjects affected by this condition remain underdeveloped. This applies to many aspects of the 
condition including the Gastrointestinal (GI) symptoms. Only recently has research highlighted 
the GI involvement in ASD as a potential component for assessment and treatment [6-9], although 
for more than a decade there have been studies undertaken on the possible link between GI 
abnormalities and the associated behavioral problems of ASD [8,10]. Horvath et al., (1999) after 
analyzing 36 autistic children suffering from GI symptoms found an incidence of reflux oesophagitis 
in 69%, while 88% presented with abdominal discomfort and 67% presented with chronic non-
specific duodenal inflammation. Data from this study indicated that more than half of the subject 
population had Duodenal Paneth Cell hyperplasia and presented with abdominal pain, chronic 
diarrhea, bloating, sleep disturbance and/or irritability [11]. A gut-brain axis has been postulated 
as a link between these gut metabolic reactions and abnormal behaviour potentially indicating an 
important component of neural development [12,13]. This potential link has been given support by 
Jyonouchi et al., (2005) who postulated an intrinsic defect in the innate immune responses in ASD 
and thus a possible link between the GI system and behavioral symptoms mediated by immune 
responses [14,15].
Several authors such as Forsythe et al. [16]; Horvath et al. [11]; Jyonouchi et al. [17]; K. L. Reichelt 
and A. M. Knivsberg [18]; Nikolov et al. [19];  Walker et al. [9] have suggested a possible gut-
brain axis that could be immunological, inflammatory or genetic in nature. A possible connection 
between the behavioral signs and symptoms and the gastrointestinal condition in these children 
has been suggested by Buie et al. [20]. Also, the lack of an appropriate low-invasive gastrointestinal 
treatment prompted separate part of this present study to consider addressing this lack [21].
Smith et al., (2009) reported that 35% of parents of autistic children in special schools were 
concerned with their child’s bowel function compared with 4% of parents of children in mainstream 
schools. The same study also reported that the presence of constipation (25%), diarrhea (27%) and 
flatulence (24%) were significantly higher in children with PDD compared with a control group of 
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healthy subjects which was 4%, 5% and 2% respectly. Although Black 
et al. (2002) postulated that there was no specific GI patho-physiology 
in autistic children, the increased bowel symptoms in these children 
are suggestive of some bowel dysfunction [7,9,22,23].
There are a number of methods of determining bowel 
inflammation including biopsy, endoscopy, and colonoscopy and 
stool analysis for biochemical markers [24,25]. The least invasive, 
particularly important in children, utilizes faecal biochemical markers 
including the S100 group of proteins [26].
Calprotectin is one such marker and it is known that high levels 
of this S100 protein leave with the intracellular exudates fluid during 
various inflammatory processes [27-29] and once released from the 
cell it may be detected in serum and body fluids as a useful marker for 
inflammatory processes.
A high Calprotectin concentration is thought to be derived from 
either stimulated neutrophil secretion or as a result of cell death [27]. 
An example of high Calprotectin levels occurs in the faeces of patients 
suffering from Inflammatory Bowel Disease (IBD) such as Crohn’s 
Disease (CD) and Ulcerate Colitis (UC) [30]. 
Currently the main application for the Calprotectin ELISA 
test is to differentiate between IBD and Irritable Bowel Syndrome 
(IBS) [31]. Calprotectin concentration levels are decreased during 
successful IBD therapy and higher concentration levels may be an 
indicator of IBD relapse [32]. Assessing faecal Calprotectin has been 
found to be a reliable diagnostic tool for patients who present with 
IBD symptoms [33]. Further, a meta-analysis by Van Rheenen et al 
(2010) determined that the Calprotectin prediction of inflammation 
in adults gave a sensitivity of 93% and specificity of 96%. The 
corresponding values for children and teenagers were 92% and 76% 
respectively. Calprotectin has been used as a non-invasive marker for 
identifying organic disease of the GI tract and it has been suggested 
that it could be used before more invasive procedures [34-36]. The 
faecal calprotectin ELISA has proved to be a valuable tool compared 
to more invasive GI tests, especially in young children [34,37] and 
according the NICE diagnostic guidance DG11 (2013) calprotectin is 
recommend as an option to distinguish between IBD and IBS.
The aim of this study was to determine whether a correlation exists 
between the very stable faecal GI inflammatory marker Calprotectin 
and the perception of parents of autistic children to the children’s 
GI signs/symptoms. A modified Secretin Outcome Survey (S.O.S) 
twenty-four-parameter questionnaire [38] was used to assess parents’ 
perceptions and a standard ELISA test used to assess Calprotectin in 
the stools of the children.
Material and Methods
The study is a clinical trial employing a longitudinal design with a 
calculated (Power Analysis) sample size of 50 subjects.
Children between 3½ and 8 years old were recruited from schools 
dedicated to autistic children and in response to announcements 
placed in local newspapers and magazines, in state schools, 
Universities and on the National Autistic Society research subject 
recruitment website.
Population
The population for the current study was composed of male and 
female autistic children aged between 3½ and 8 years. All subjects 
recruited to this study were independently diagnosed by specialist 
professionals prior to their inclusion in the study. All the specialist 
professionals in England and Wales are required to follow the DSM-
4 and ICD-10 diagnostic criteria to release a Diagnostic Statement. 
Parents were required to provide the Diagnostic Statement, together 
with the statement of special educational needs provided by the 
ELB, prior to any contact with the researcher. The researcher did 
not make any contribution to the diagnostic process, thus avoiding 
classification bias on recruitment. 
After the initial recruitment/screening questionnaire, parents 
were interviewed by a single senior osteopath/researcher with 16 years 
of clinical experience. The interview consisted of a one and half hour 
conversation with the mother and/or father when a thorough case 
history was taken. The case history was divided into pre-natal history, 
pregnancy, labour, medication during labour, developmental stages 
of the child, any accidents or surgeries, past and present medication, 
when a child was diagnosed as autistic, who diagnosed the child, 
present symptoms, GI symptoms (including colour of stools, their 
frequency, consistency, and smell), behavioral symptoms (flapping of 
hands, eye contact, communication, etc.) current diet and allergies. 
From this it was determined whether the subject complied with all 
the inclusion criteria. It is important to highlight that data analysis of 
parameters collected from the parental interview was not part of this 
study and therefore not performed. The interview was solely used to 
assess whether subjects complied with the inclusion criteria. 
In total, 64 children were recruited to the study [Figure 1]. Ten 
subjects were excluded due either to a compromising underlying 
condition or to not presenting with GI symptoms. Further parents 
of autistic children completed the interview but did not comply with 
sending the first set of stool samples and the questionnaires necessary 
to participate in the study and so were classified as drop outs. The 
final sample therefore comprised of 49 autistic children (46 male and 
3 female) aged between 3½ and 8 years.
An essential inclusion criterion was that subjects had been 
Figure 1: Flow chart indicating the recruitment process and final 
sample size. 
Note: The flowchart indicates the number of subjects recruited, excluded 
subjects, dropouts, and the final subject number.
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diagnosed as Autistic (ASD) by independent medical specialists 
prior to entry to the study. Thus, recruits needed to be enrolled at a 
special school for autistic children accredited by the National Autistic 
Society. The rationale for this requirement lay in the fact that the 
special schools for autistic children in England and Wales only accept 
children who have been given a statement of special educational needs 
(a legal document) by the Education and Library Board (ELB) after 
being assessed by an appropriate, experienced specialist. All included 
subjects were suffering from abnormal behaviour recognized by 
DSM-4 and ICD-10 Diagnostic Criteria, as well as suffering from GI 
symptoms e.g. abdominal distension and pain, constipation, chronic 
diarrhea, foul-smelling stools and/or flatulence.
Subjects were withdrawn from the study if the child developed a 
condition that could jeopardise general health e.g. infections.
The project was granted Ethical approval by both The British 
College of Osteopathic Medicine Ethics Committee and by the 
University of Westminster Ethics Committee.
The subjects’ GI and behavioral symptoms were assessed via S.O.S 
questionnaires [38] completed by the parents. Laboratory analysis 
of collected stool samples to assess Calprotectin concentration 
was undertaken by a specialist, independent facility blinded to the 
questionnaires (Department of Clinical Biochemistry, King’s College 
Hospital, London).
Questionnaire - Autism Research Institute Secretin Outcomes 
Survey Form - “S.O.S Form”
Questionnaires are useful data collection tools to analyze a 
patient’s perception of health [39]. The current study used the S.O.S 
Form, a validated and standardized questionnaire [38,40-45], to 
measure the parents’ perception of their autistic children. Benefits 
of using questionnaires for data collection includes the relatively low 
administration costs ease of response and simplicity of data analysis 
[39]. 
The health community usually uses a Likert-type or frequency 
scale questionnaire designed to measure attitudes or opinions. In 
this study, parents completed the S.O.S questionnaire regarding 
their assessment of the GI and behavioral symptoms of their children 
which consists of a 24 parameter, ten-point Likert scale, based on the 
Autism Research Institute Secretin Outcomes Survey Form - “S.O.S 
Form” [38,40-45].
The Likert scale assumes linearity of the data, measuring, for 
example, parameters from strongly agree to strongly disagree. It is 
important to demonstrate the reliability of the S.O.S questionnaires 
used. The most common test to analyse internal consistency and 
reliability of a multiple Likert scale questionnaire or survey is the 
Cronbach’s Alpha (α) statistic. Cronbach’s α score above 0.7 are 
considered acceptable for reliability [46,47].
Chronbach’s Alpha analysis, a coefficient of reliability (or internal 
consistency), was conducted on the S.O.S questionnaire to evaluate 
reliability. The overall reliability of the S.O.S questionnaire was 0.881 
on Chronbach’s Alpha Scale suggesting a good internal consistency.
Procedure
All subjects followed the same procedure: 
Parents were invited to attend a meeting at their child’s school to:
•  receive guidelines about the research.
•  sign the consent form authorizing the child to be part of the study
•  complete an initial recruitment/screening questionnaire about 
the child’s history. This questionnaire was used only as a tool 
for the authors to determinate whether the child would fit the 
inclusion criteria of the research. 
•  Arrange an interview with the lead author. This interview consisted 
of a one and half hour conversation with the parent/s when a 
thorough case history was taken. The case history gave important 
base line information and acted as a further determinant that the 
subject complied with the inclusion criteria.
Parents were instructed on how to collect the stool samples. They 
were informed of the need to answer the S.O.S questionnaire on the 
same occasion as the stool was collected. This resulted in matching 
dates for each stool sample and S.O.S questionnaire. This process 
was repeated eight times over ten weeks. Parents were informed that 
the S.O.S questionnaire was a key tool for the measurement of their 
child’s behaviour and GI function.
Stool Samples
Calprotectin is remarkably stable in stools. It can be stored at 
room temperature in a suitable container for up to seven days [29]. 
Samples can be transported in authorized containers (Safebox) 
requiring no refrigeration and then stored frozen at -18°C or lower 
until the time of analysis. Exposure to a temperature higher than 30°C 
was avoided. 
Stool samples were collected by parents from a potty or 
nappy and placed in a polystyrene screw cap tube with caps coded 
for identification. Parents received eight ‘Safeboxes’ numbered 
sequentially from 1 to 8 making it easy to identify the appropriate 
box to be sequentially dispatched. Parents were asked only to date 
the sample tube and the form inside the ‘Safebox’ which contained 
the subject identification. The ‘Safebox’ was sent to King’s College 
Hospital where it was stored at minus 20°C for later analysis.
After the specimen collection, parents had a window of up to 
seven days to post the sample. In cases where the subject was not able 
to provide a sample to be posted on the set date, parents were asked 
to attempt to send a sample and complete the questionnaire within a 
window of two days of the predetermined set date. This maintained 
the matched dates for the samples sent to King’s College Hospital 
and questionnaires posted to the lead author. This process facilitated 
statistical correlation analysis between sample and questionnaire.
ELISA Test Protocol
Calprotectin ELISA plates [48] were used. Authors were blind 
to the assay results until completion of the study. ELISA plates 
were purchased from Bühlmann Laboratories AG-Switzerland. 
The procedure has been described previously by Manz et al (2012). 
Faecal extracts were prepared by using 40-100 mg of faeces, avoiding 
any undigested solid material like fibers and seeds, were placed in 
a pre-weighed, empty, screw-capped tube. Pre-diluted buffer was 
added, 1:50, weight/volume, and the suspension mixed vigorously 
for 30 seconds. The suspension was then mixed for a further 30 +/-5 
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minutes using a shaker at approximately 1000 rpm, with a loop inside 
the tube as an agitator. A small amount of the mixture (1-2 mL) was 
then transferred to an Eppendorf tube and centrifuged at 10,000g for 
20 minutes at +4°C. The supernatant was harvested and this extract 
used in the ELISA. A total volume of approximately 0.5 ml was taken 
and used either for the assay or stored, frozen. The calculations were 
performed by a computer linked to the ELISA reader; quality controls 
were included in each run. Stool concentration of calprotectin was 
calculated as µg/g of faeces. Values above 50 µg/g are considered a 
positive calprotectin test. 
Data Collection Procedure
Data collected was analyzed using ‘R’ statistical package software 
version 2.15 [50]. 
Subjects’ GI inflammation was assessed using faecal Calprotectin 
while GI and behavioral symptoms were assessed using the twenty-
four-parameter S.O.S questionnaire [38] (Table 1). This was 
completed by the parents on eight occasions.
A Mixed Effect Model was used to analyses the repeated 
observations for this longitudinal study. In this model the analysis 
takes into consideration missing data which could potentially have 
an effect on the end results, an inherent problem of longitudinal 
studies [51]. The Mixed Effect Model is used to correlate the repetite 
measures and it also measures the within and between subject error. 
A mixed effect model has been employed for the analysis of the data 
generated by longitudinal studies [51,52] (Table 2).
Results
From a total recruitment of sixty-four autistic children fifty-
Table 1: Questionnaire parameters used to assess behavioral and 
gastrointestinal symptoms.
Social behaviour and communication
1. Lack of awareness and interaction with parent
2. Abnormal greeting behaviour
3. Abnormal comfort seeking
4. Can’t make friends
5. Lack of awareness of social rules
6. Lack of spontaneous speech
7. Abnormal word utilization
8. Poor comprehension of verbal instructions
9. Lack of eye contact
10. Abnormal repetitive gestures
11. Need to maintain sameness
12.  Need of fixed routine
13. Diarrhoea
14. Constipation
15. Poor Appetite
16. Bloating
17. Flatulence
18. Vomiting
19. Unhappy
20. Aggressive
21. Destructive
22. Spaced out/ Non-Interactive
23. Agitated
24. Disagreeable
Note: The Likert Scale of signs severity: 0= never shows this particular sign or 
behaviour; 1= slight/unobtrusive; 2; 3 = mild; 4; 5= moderate; 6; 7= severe; 8; 
9=extreme/incapacitating.
Table 2: Raw data from Calprotectin stool samples.
 Cal 1 Cal 2 Cal 3 Cal 4 Cal 5 Cal 6 Cal 7 Cal 8
Subject 
Number 49 49 49 49 44 42 43 35
Mean 46.2 76.8 54.2 33.5 45.8 28.6 40.8 62.9
S.D 92.8 239.6 99.3 57.8 97.2 31.2 46.7 114.0
Range 26.3-
511
28.6-
1582
44.7-
630
25.3-
381
22.6-
472
24-
127
42.3-
236
40.5-
473
Note: Mean Data has been calculated from the total data (49 subjects multiplied 
by 8 Samples from each subject giving a total spreadsheet of 392 cells). Table 2 
shows the mean data from the total cells.
two satisfied the inclusion criteria and forty-nine entered the study 
[Figure 1]. 
Association between questionnaire data and Calprotectin 
adjusted by patient and sample
The data generated from the set of eight S.O.S questionnaires, from 
each subject, were correlated with the results of the corresponding 
eight sets of faecal Calprotectin. Twenty-four parameters from the 
questionnaires were matched with faecal sample collecting times 
and results. Each parameter from the questionnaire was analyzed 
individually using a unvariate model. 
Table 3 shows all the results of the unvariate analysis. This is 
commonly used in prediction research and it includes all the unvariate 
variables tested. The results with P value ˃0.15 were manually deleted 
and were not included in the multivariate model. Each parameter was 
analyzed repeatedly at several points in time and corrected by patient 
and by sample and correlated to Calprotectin samples. Unvariate 
analysis is an established strategy to measure longitudinal data, single 
outcome variables [53]. With the aim of keeping variables in the 
regression model a more liberal p value of 0.15-0.25 was used. This 
is established as a common procedure in predictor research [54,55]. 
A p value of <0.15 was set as an initial filter for the unvariate model 
analysis [56,57]. The parameters ‘Lack of awareness and interaction 
with parent’ (𝑝=0.02), ‘Abnormal repetite gestures’ (𝑝=0.009), ‘Need 
to maintain sameness’ (𝑝=0.0093) and ‘Need for a fixed routine’ 
(𝑝=0.003) are significant. The parameters Constipation (𝑝=0.108) and 
Bloating (𝑝=0.086) are not significant at p<0.05, but both parameters 
fit the required filter criteria with p<0.15 to be incorporated in the 
multivariate analysis.
The data indicates a strong association between several parameters 
from the S.O.S questionnaire and levels of faecal Calprotectin. 
The parameter ‘need for a fixed routine’ was highly significant 
(𝑝<0.00009), with a Multivariate Coefficient of 3.227 suggesting that 
autistic children who display an increase in ‘need for a fixed routine’ 
also show elevated Calprotectin which indicates gastrointestinal 
inflammation. Paradoxically, the parameter ‘constipation’ although 
showing a significant change (𝑝<0.02) has a negative Multivariate 
Coefficient (-1.584), corresponding to a decrease in Calprotectin 
levels, indicating an inverse relationship between ‘constipation’ and 
Calprotectin. The negative value in the parameter ‘constipation’ 
appears to be associated with a positive value of ‘need for a fixed 
routine’ which may, therefore, be considered independent, but 
reciprocal, predictors of gastrointestinal inflammation in these 
autistic children.
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Discussion
This longitudinal study sought to investigate twenty-four 
parameter questionnaire (S.O.S questionnaire) [Table 1] and 
determine whether a correlation existed with the biochemical marker 
Calprotectin [Table 2]. 
The study found significant correlation between the behavioral 
parameters ‘need for a fixed routine’ and ‘constipation’, and the 
inflammatory biochemical faecal marker Calprotectin. These results 
suggest that these two parameters, ‘need for a fixed routine’ and 
‘constipation’, could be used together in an initial, standardized, 
screening questionnaire as a simple to use, non-invasive and 
inexpensive predictor of inflammatory bowel processes in young 
autistic children. 
Table 4: Final Univariate Model.
Variable p set at <0.15 used as an initial filter
1. Lack of awareness and interaction 
with parent 0.0200
2. Abnormal repetitive gestures 0.0009
3. Need to maintain sameness 0.0093
4. Need of a fixed routine 0.0003
5. Constipation 0.108
6. Bloating 0.086
Note: Table 4 includes all the variables that satisfied the initial filter of p<0.15 
in the univariate analysis of the mixed effect model. The parameters 1-4 have 
shown a significant correlation with the inflammatory marker Calprotectin with 
p<0.05. The parameters constipation and bloating although not significant in 
the univariate model have shown a p value <0.15 which satisfies the filter value 
required to be included in a multivariate model.
Table 3: Initial Univariate Model data.
Variable Std Error p-value
1. Lack of awareness and interaction with parent 0.90 0.02*
2. Abnormal greeting behaviour 0.81 0.35
3. Abnormal comfort seeking 0.81 0.32
4. Can’t make friends 0.66 0.80
5. Lack of awareness of social rules 0.70 0.79
6. Lack of spontaneous speech 1.15 0.28
7. Abnormal word utilisation 0.67 0.69
8. Poor comprehension of verbal instructions 0.77 0.32
9. Lack of eye contact 0.92 0.57
10. Abnormal repetitive gestures 0.77 0.009
11. Need to maintain sameness 0.78 0.009*
12. Need of fixed routine 0.79 0.0003*
13. Diarrhoea 0.78 0.86
14. Constipation 0.69 0.10*
15. Poor Appetite 0.74 0.65
16. Bloating 0.76 0.08*
17. Flatulence 0.85 0.41
18. Vomiting 1.26 0.39
19. Unhappy 1.07 0.35
20. Aggressive 0.89 0.20
21. Destructive 0.82 0.36
22. Spaced out/ Non Interactive 0.79 0.14
23. Agitated 0.91 0.22
24. Disagreeable 0.82 0.01*
Note: This table includes all the Univariate variables tested as is commonly the 
practice in prediction research. The P values of <0.15 were manually deleted and 
were not included on the multivariate model. P values indicated by the asterisks 
were kept in the multivariate model.
Table 5: Final Multivariate Model.
Variable Multivariate 
Coefficient
SE p-value
(Intercept)* 22.894636 4.023740 p set at < 
0.05
Need of a fixed 
Routine 3.226851 0.813211 0.00009
Constipation -1.584028 0.69109 0.02269
Note: Table 5 represents the final Multivariate model results with two significant 
parameters. Need for a fixed routine (p=0.00009) and constipation (p=0.02) were 
found to correlate with GI inflammation as assessed using Calprotectin.
* Intercept is a baseline for Calprotectin value in this multivariate model
The results from the unvariate study [Tables 4 and 5], indicate a 
further four parameters with a possible association with Calprotectin 
values. Although they are not independent predictors of GI 
inflammation, they could be appropriately included in combination 
with the two multariable parameters ‘need for a fixed routine’ and 
‘constipation’. 
The final set of six parameters could be used as an initial, short, 
standard questionnaire in clinical settings simplifying the diagnostic 
process enabling cost efficiency and more effectively directing subjects 
to further diagnostic examination as appropriate. Combining these 
six parameters into one single questionnaire could enable reduction 
of the number of parameters to be tested, from twenty-four to six, 
without loss of power or sensitivity. A standardized six parameter 
questionnaire would not replace any other form of diagnostic testing 
for gastrointestinal inflammation, but it could be a cost effective, non-
invasive initial screen for clinical diagnosis.
These results tend to support a brain-gut axis theory that has 
been previously postulated [12,13,58]. The correlation between the 
behavioral characteristics of: ‘Lack of Awareness and interaction with 
parent’, ‘Abnormal repetitive gestures’, ‘Need to maintain sameness’, 
‘Need of a fixed routine’, ‘Constipation’ and ‘Bloating’ and the 
inflammatory biochemical marker Calprotectin, may be indicative 
of a connection between gut responses and the classic emotional 
behaviour suffered by autistic children.
Limitations
One of the limitations of the study is that low spectrum autistic 
children usually lack the ability to describe or grade their own 
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symptoms. Therefore, the results from the questionnaires relied on the 
parents’ perception of their child’s symptoms and it was not possible 
to determine how the subject personally felt. This limitation may 
possibly result in parents over or under estimating the rating value 
on the Likert scale, potentially creating bias in the results. A blinded, 
independent assessor rating the parameters could possibly prevent 
introduction of this bias. However, the professional would have to 
get acquainted with the child to be able to rate the questionnaire 
accurately and might still not perceive changes that parents are more 
aware of. Moreover, this solution would not be as cost effective as 
the introduction of independent professionals would substantially 
increase the cost of the research.
Another limitation to this study was that the patients were self-
referred. However, all possible measures were taken to safeguard 
the inclusion criteria of the research. One of them, presented in the 
methodology section, was that the subjects were required to present 
a formal diagnosis of autism and be assigned to a special school 
for autistic children registered by the National Autistic Society. All 
subjects were formally diagnosed following the same diagnostic 
criteria required by the DSM-4 and the ICD-10. However, children 
were not diagnosed by the same diagnostic centre or by the same 
professional and, therefore, it is not possible to know the impact of 
that on the results of the study. It is not known if there were any initial 
discrepancies in interpretation of the autism diagnosis. Future studies 
may benefit by using a single centre that would refer subjects to the 
initial screening research procedure. Participating patients could 
then be selected to be on the same level of the autistic spectrum and 
perhaps gender could also be selected and standardized. However, 
recruiting equal numbers of male and female subjects selected from 
a random sample of autistic subjects is a challenge due the high 
prevalence of males diagnosed as autistic [1,59,60]. The same idea 
applies to the GI signs and symptoms of the subjects included in this 
research. Parents were self-referring their children to the study and 
there was no formal diagnosis from a gastroenterologist. However, 
according to Chandler, et al [61] and Gorrindo, et al [8] there is a high 
concordance between parental reporting and the gastroenterologist’s 
evaluation of GI symptoms in autistic children. This research relied 
on parents’ perceptions of GI signs and symptoms. Even though 
studies claimed high concordance between the perception of the 
parents and the evaluation from the medical doctor, this research 
might have missed subtypes of gastrointestinal conditions that could 
have affected the results. Possibly, this could have been prevented 
if a gastroenterologist were part of the project and had been given 
responsibility for the screening process. However, that would have 
imposed financial constraints beyond the scope of this research. 
Conclusion
From the study results it may be possible to create a simple to 
use reliable, non-invasive and inexpensive screening tool capable 
of evaluating GI inflammation in autistic children. The final 6 item 
questionnaire could be easily completed by parents or guardians and 
could potentially facilitate initial screening of GI inflammation in 
autistic children.
This study attempted to explore the use of a non-invasive clinical 
tool, the questionnaire, in the facilitation of the analysis of possible GI 
dysfunction in autistic children. 
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